CytoDyn Inc. (OTCQB: CYDY) presented early clinical and biomarker results from its Phase 2 CLOVER study of leronlimab in metastatic colorectal cancer (mCRC) at the AACR Annual Meeting 2026, held April 17–22 in San Diego. The poster, titled “Preliminary results of a phase 2 study of leronlimab in combination with TAS‑102 and bevacizumab in previously treated metastatic colorectal cancer,” was delivered by Dr. Pashtoon M. Kasi on April 21, 2026.
The presentation highlighted early biomarker activity, including rapid reductions in circulating tumor DNA and modulation of immune‑related markers. Dr. Kasi noted, “Preliminary results from our ongoing Phase 2 study suggest that CCR5 inhibition with leronlimab may enhance both biomarker and clinical responses in heavily pre‑treated mCRC patients.” These findings support the hypothesis that CCR5 inhibition can enhance immune engagement in this difficult‑to‑treat population.
CytoDyn’s oncology program is actively pursuing leronlimab in several indications, including metastatic triple‑negative breast cancer and mCRC. The data represent the first prospective evidence of leronlimab’s activity in a heavily pre‑treated mCRC cohort, a critical milestone that could broaden the drug’s therapeutic scope and inform future development plans. Enrollment for the Phase 2 study was completed on April 21, with over 60 patients enrolled, and additional data are expected to guide subsequent clinical decisions.
The market reaction to the presentation was muted, with retail sentiment on Stocktwits remaining extremely bullish. While the data are encouraging, investors appear to be awaiting more mature clinical outcomes before reassessing the company’s valuation.
CytoDyn’s early mCRC data underscore the potential of leronlimab to modulate the tumor microenvironment and enhance anti‑tumor immunity. The company will continue to monitor the study’s progression and integrate these insights into its broader oncology strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.